PortalPublikationenCYP2B6*6 is associated with increased breast cancer risk

CYP2B6*6 is associated with increased breast cancer risk

Standard

CYP2B6*6 is associated with increased breast cancer risk. / Justenhoven, Christina; Pentimalli, Daniela; Rabstein, Sylvia; Harth, Volker; Lotz, Anne; Pesch, Beate; Brüning, Thomas; Dörk, Thilo; Schürmann, Peter; Bogdanova, Natalia; Park-Simon, Tjoung-Won; Couch, Fergus J; Olson, Janet E; Fasching, Peter A; Beckmann, Matthias W; Häberle, Lothar; Ekici, Arif; Hall, Per; Czene, Kamilla; Liu, Janjun; Li, Jingmei; Baisch, Christian; Hamann, Ute; Ko, Yon-Dschun; Brauch, Hiltrud.

in: INT J CANCER, Jahrgang 134, Nr. 2, 15.01.2015, S. 426-30.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Justenhoven, C, Pentimalli, D, Rabstein, S, Harth, V, Lotz, A, Pesch, B, Brüning, T, Dörk, T, Schürmann, P, Bogdanova, N, Park-Simon, T-W, Couch, FJ, Olson, JE, Fasching, PA, Beckmann, MW, Häberle, L, Ekici, A, Hall, P, Czene, K, Liu, J, Li, J, Baisch, C, Hamann, U, Ko, Y-D & Brauch, H 2015, 'CYP2B6*6 is associated with increased breast cancer risk', INT J CANCER, Jg. 134, Nr. 2, S. 426-30. https://doi.org/10.1002/ijc.28356

APA

Justenhoven, C., Pentimalli, D., Rabstein, S., Harth, V., Lotz, A., Pesch, B., Brüning, T., Dörk, T., Schürmann, P., Bogdanova, N., Park-Simon, T-W., Couch, F. J., Olson, J. E., Fasching, P. A., Beckmann, M. W., Häberle, L., Ekici, A., Hall, P., Czene, K., ... Brauch, H. (2015). CYP2B6*6 is associated with increased breast cancer risk. INT J CANCER, 134(2), 426-30. https://doi.org/10.1002/ijc.28356

Vancouver

Justenhoven C, Pentimalli D, Rabstein S, Harth V, Lotz A, Pesch B et al. CYP2B6*6 is associated with increased breast cancer risk. INT J CANCER. 2015 Jan 15;134(2):426-30. https://doi.org/10.1002/ijc.28356

Bibtex

@article{05dd2957add74ec0ab17910c0e067d47,
title = "CYP2B6*6 is associated with increased breast cancer risk",
abstract = "The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. The GENICA breast cancer case-control study showed associations between the variant genotypes CYP2B6_516_TT and CYP2B6_785_GG and breast cancer risk with odds ratios (ORs) of 1.34 (p = 0.001) and 1.31 (p = 0.002), respectively. A similar effect was observed for carriers of the CYP2B6_516_T allele in a validation study including four independent studies from Germany, Sweden and USA. In a pooled analysis of all five studies involving 4,638 breast cancer cases and 3,594 controls of European ancestry, carriers of the CYP2B6_516_G and the CYP2B6_785_G variant had an increased breast cancer risk with ORs of 1.10 (p = 0.027) and 1.10 (p = 0.031), respectively. We conclude that the genetic variants CYP2B6_516_G and CYP2B6_785_G (designated CYP2B6*6), which are known to decrease activity of the CYP2B6 enzyme, contribute to an increased breast cancer risk.",
keywords = "Adult, Aged, Aged, 80 and over, Aryl Hydrocarbon Hydroxylases, Breast Neoplasms, Case-Control Studies, Female, Follow-Up Studies, Genetic Predisposition to Disease, Genotype, Humans, Meta-Analysis as Topic, Middle Aged, Polymorphism, Genetic, Prognosis, Risk Factors, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Tumor Markers, Biological",
author = "Christina Justenhoven and Daniela Pentimalli and Sylvia Rabstein and Volker Harth and Anne Lotz and Beate Pesch and Thomas Br{\"u}ning and Thilo D{\"o}rk and Peter Sch{\"u}rmann and Natalia Bogdanova and Tjoung-Won Park-Simon and Couch, {Fergus J} and Olson, {Janet E} and Fasching, {Peter A} and Beckmann, {Matthias W} and Lothar H{\"a}berle and Arif Ekici and Per Hall and Kamilla Czene and Janjun Liu and Jingmei Li and Christian Baisch and Ute Hamann and Yon-Dschun Ko and Hiltrud Brauch",
note = "{\textcopyright} 2013 UICC.",
year = "2015",
month = jan,
day = "15",
doi = "10.1002/ijc.28356",
language = "English",
volume = "134",
pages = "426--30",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - CYP2B6*6 is associated with increased breast cancer risk

AU - Justenhoven, Christina

AU - Pentimalli, Daniela

AU - Rabstein, Sylvia

AU - Harth, Volker

AU - Lotz, Anne

AU - Pesch, Beate

AU - Brüning, Thomas

AU - Dörk, Thilo

AU - Schürmann, Peter

AU - Bogdanova, Natalia

AU - Park-Simon, Tjoung-Won

AU - Couch, Fergus J

AU - Olson, Janet E

AU - Fasching, Peter A

AU - Beckmann, Matthias W

AU - Häberle, Lothar

AU - Ekici, Arif

AU - Hall, Per

AU - Czene, Kamilla

AU - Liu, Janjun

AU - Li, Jingmei

AU - Baisch, Christian

AU - Hamann, Ute

AU - Ko, Yon-Dschun

AU - Brauch, Hiltrud

N1 - © 2013 UICC.

PY - 2015/1/15

Y1 - 2015/1/15

N2 - The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. The GENICA breast cancer case-control study showed associations between the variant genotypes CYP2B6_516_TT and CYP2B6_785_GG and breast cancer risk with odds ratios (ORs) of 1.34 (p = 0.001) and 1.31 (p = 0.002), respectively. A similar effect was observed for carriers of the CYP2B6_516_T allele in a validation study including four independent studies from Germany, Sweden and USA. In a pooled analysis of all five studies involving 4,638 breast cancer cases and 3,594 controls of European ancestry, carriers of the CYP2B6_516_G and the CYP2B6_785_G variant had an increased breast cancer risk with ORs of 1.10 (p = 0.027) and 1.10 (p = 0.031), respectively. We conclude that the genetic variants CYP2B6_516_G and CYP2B6_785_G (designated CYP2B6*6), which are known to decrease activity of the CYP2B6 enzyme, contribute to an increased breast cancer risk.

AB - The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. The GENICA breast cancer case-control study showed associations between the variant genotypes CYP2B6_516_TT and CYP2B6_785_GG and breast cancer risk with odds ratios (ORs) of 1.34 (p = 0.001) and 1.31 (p = 0.002), respectively. A similar effect was observed for carriers of the CYP2B6_516_T allele in a validation study including four independent studies from Germany, Sweden and USA. In a pooled analysis of all five studies involving 4,638 breast cancer cases and 3,594 controls of European ancestry, carriers of the CYP2B6_516_G and the CYP2B6_785_G variant had an increased breast cancer risk with ORs of 1.10 (p = 0.027) and 1.10 (p = 0.031), respectively. We conclude that the genetic variants CYP2B6_516_G and CYP2B6_785_G (designated CYP2B6*6), which are known to decrease activity of the CYP2B6 enzyme, contribute to an increased breast cancer risk.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Aryl Hydrocarbon Hydroxylases

KW - Breast Neoplasms

KW - Case-Control Studies

KW - Female

KW - Follow-Up Studies

KW - Genetic Predisposition to Disease

KW - Genotype

KW - Humans

KW - Meta-Analysis as Topic

KW - Middle Aged

KW - Polymorphism, Genetic

KW - Prognosis

KW - Risk Factors

KW - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

KW - Tumor Markers, Biological

U2 - 10.1002/ijc.28356

DO - 10.1002/ijc.28356

M3 - SCORING: Journal article

C2 - 23824676

VL - 134

SP - 426

EP - 430

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 2

ER -